Xia Xin, Pethe Kevin, Kim Ryangyeo, Ballell Lluis, Barros David, Cechetto Jonathan, Jeon HeeKyoung, Kim Kideok, Garcia-Bennett Alfonso E
Department of Materials and Environmental Chemistry, Arrhenius Laboratory, Stockholm University, Stockholm SE-106 91, Sweden.
Nanologica AB, Drottning Kristinas Väg 61, Stockholm SE-114 28, Sweden.
Nanomaterials (Basel). 2014 Sep 11;4(3):813-826. doi: 10.3390/nano4030813.
Tuberculosis is a major problem in public health. While new effective treatments to combat the disease are currently under development, they tend suffer from poor solubility often resulting in low and/or inconsistent oral bioavailability. Mesoporous materials are here investigated in an intracellular assay, for the effective delivery of compound PA-824; a poorly soluble bactericidal agent being developed against Tuberculosis (TB). Mesoporous materials enhance the solubility of PA-824; however, this is not translated into a higher antibacterial activity in TB-infected macrophages after 5 days of incubation, where similar values are obtained. The lack of improved activity may be due to insufficient release of the drug from the mesopores in the context of the cellular environment. However, these results show promising data for the use of mesoporous particles in the context of oral delivery with expected improvements in bioavailability.
结核病是公共卫生领域的一个重大问题。虽然目前正在研发对抗该疾病的新型有效治疗方法,但这些方法往往存在溶解度差的问题,常常导致口服生物利用度低和/或不稳定。本文在细胞内试验中研究了介孔材料用于有效递送化合物PA - 824的情况;PA - 824是一种正在研发的用于对抗结核病(TB)的难溶性杀菌剂。介孔材料提高了PA - 824的溶解度;然而,在孵育5天后,在感染结核杆菌的巨噬细胞中,这并没有转化为更高的抗菌活性,得到的数值相似。活性没有提高可能是由于在细胞环境中药物从介孔中的释放不足。然而,这些结果为介孔颗粒在口服给药方面的应用显示出了有前景的数据,预计生物利用度会有所提高。